This Article Full Text Full Text (PDF) All Versions of this Article: 22/4/692    most recent 01.ATV.0000012802.69414.A8v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Baetta, R. Articles by Tremoli, E. Search for Related Content PubMed PubMed Citation Articles by Baetta, R. Articles by Tremoli, E. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Carotid Artery Disease Hazardous Substances DB CHOLESTEROL Related Collections Arterial thrombosis Cardiovascular Pharmacology Animal models of human disease Pathophysiology

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2002;22:692.)
© 2002 American Heart Association, Inc.

Thrombosis

Fluvastatin Reduces Tissue Factor Expression and Macrophage Accumulation in Carotid Lesions of Cholesterol-Fed Rabbits in the Absence of Lipid Lowering

Roberta Baetta^*; Marina Camera^*; Carmen Comparato; Caterina Altana; Michael D. Ezekowitz; Elena Tremoli

From the Department of Pharmacological Sciences (R.B., M.C., C.C., C.A., E.T.), University of Milan, Milan, Italy; Monzino Cardiologic Center IRCCS (M.C., E.T.), Milan, Italy; and MCP Hahnemann University (M.D.E.), Philadelphia, Pa.

Reprint requests to Prof Elena Tremoli, Department of Pharmacological Sciences, Via Balzaretti 9, 20133 Milan, Italy. E-mail Elena.Tremoli{at}unimi.it

The expression of tissue factor (TF), mainly by infiltrated inflammatory cells, has been shown to be responsible for the thrombogenicity associated with atheroma. The contribution of the nonlipid-related effects of statins to the clinical benefits of statin therapy is currently under intense investigation. In this study, we evaluated the ability of fluvastatin to modulate TF expression and macrophage accumulation in rabbit carotid intimal lesions independently of cholesterol lowering. Male rabbits were fed for 30 days a 1% cholesterol-rich diet with or without fluvastatin at 5 mg/kg per day. Two weeks from the start of treatment, a silastic collar was placed around the carotid artery. Fifteen days later, the animals were killed, and carotid segments were excised and processed. The atherogenic diet caused a consistent increase in plasma cholesterol levels (610±231 mg/dL versus 50±9 mg/dL at baseline), which were not affected by fluvastatin (603±248 mg/dL). In the rabbits fed a high cholesterol diet without fluvastatin, an intimal lesion with macrophage accumulation and TF expression was detected. Fluvastatin significantly reduced TF and macrophage content of the lesion (-50% for both). Results indicate that fluvastatin may attenuate the inflammatory and thrombogenic potential of atherosclerotic lesions through a mechanism(s) other than cholesterol reduction, providing new insight regarding the complex mode of action of statins.

Key Words: tissue factor • thrombosis • inflammation • statins • collar model

This article has been cited by other articles:

				A. Tavridou, L. Kaklamanis, A. Papalois, A. P. Kourounakis, E. A. Rekka, P. N. Kourounakis, A. Charalambous, and V. G. Manolopoulos EP2306 [2-(4-Biphenyl)-4-methyl-octahydro-1,4-benzoxazin-2-ol, hydrobromide], A Novel Squalene Synthase Inhibitor, Reduces Atherosclerosis in the Cholesterol-Fed Rabbit J. Pharmacol. Exp. Ther., December 1, 2007; 323(3): 794 - 804. [Abstract] [Full Text] [PDF]

				R. J. Bisoendial, J. J. P. Kastelein, S. L. M. Peters, J. H. M. Levels, R. Birjmohun, J. I. Rotmans, D. Hartman, J. C. M. Meijers, M. Levi, and E. S. G. Stroes Effects of CRP infusion on endothelial function and coagulation in normocholesterolemic and hypercholesterolemic subjects J. Lipid Res., April 1, 2007; 48(4): 952 - 960. [Abstract] [Full Text] [PDF]

				S. Camino-Lopez, V. Llorente-Cortes, J. Sendra, and L. Badimon Tissue factor induction by aggregated LDL depends on LDL receptor-related protein expression (LRP1) and Rho A translocation in human vascular smooth muscle cells Cardiovasc Res, January 1, 2007; 73(1): 208 - 216. [Abstract] [Full Text] [PDF]

				E C Jury and M R Ehrenstein Statins: immunomodulators for autoimmune rheumatic disease? Lupus, March 1, 2005; 14(3): 192 - 196. [Abstract] [PDF]

				A. Undas, K. E. Brummel-Ziedins, and K. G. Mann Statins and Blood Coagulation Arterioscler. Thromb. Vasc. Biol., February 1, 2005; 25(2): 287 - 294. [Abstract] [Full Text] [PDF]

				S. Lawman, C. Mauri, E. C. Jury, H. T. Cook, and M. R. Ehrenstein Atorvastatin Inhibits Autoreactive B Cell Activation and Delays Lupus Development in New Zealand Black/White F1 Mice J. Immunol., December 15, 2004; 173(12): 7641 - 7646. [Abstract] [Full Text] [PDF]

				J. P. Werba, E. Tremoli, P. Massironi, M. Camera, A. Cannata, F. Alamanni, P. Biglioli, and A. Parolari Statins in coronary bypass surgery: rationale and clinical use Ann. Thorac. Surg., December 1, 2003; 76(6): 2132 - 2140. [Abstract] [Full Text] [PDF]

				R. Kleemann, H. M.G. Princen, J. J. Emeis, J. W. Jukema, R. D. Fontijn, A. J.G. Horrevoets, T. Kooistra, and L. M. Havekes Rosuvastatin Reduces Atherosclerosis Development Beyond and Independent of Its Plasma Cholesterol-Lowering Effect in APOE*3-Leiden Transgenic Mice: Evidence for Antiinflammatory Effects of Rosuvastatin Circulation, September 16, 2003; 108(11): 1368 - 1374. [Abstract] [Full Text] [PDF]

				A. Sambola, J. Osende, J. Hathcock, M. Degen, Y. Nemerson, V. Fuster, J. Crandall, and J. J. Badimon Role of Risk Factors in the Modulation of Tissue Factor Activity and Blood Thrombogenicity Circulation, February 25, 2003; 107(7): 973 - 977. [Abstract] [Full Text] [PDF]

				C. Kluft, R. Kleemann, and M.P.M. de Maat How best to counteract the enemies? By controlling inflammation in the coronary circulation Eur. Heart J. Suppl., November 1, 2002; 4(suppl_G): G53 - G65. [Abstract] [PDF]